Healthcare Global Enterprises has updated its investor presentation for Q3 and nine months ended December 31, 2025, incorporating certain clarifications and corrections. The company filed the updated presentation with stock exchanges on February 6, 2026, superseding the earlier version submitted on February 5, 2026.

Regulatory Filing Details

The updated investor presentation was filed under Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company requested that the earlier presentation be treated as withdrawn and superseded by the updated version.

Company Performance Highlights

The updated presentation covers Healthcare Global Enterprises' financial results for the quarter and nine months ended December 31, 2025. The company operates as India's largest pan-India oncology-focused hospital chain with presence across 19 cities and 10 states, maintaining 25 hospitals with over 2,500 capacity beds.

Leadership and Authorization

The updated filing was digitally signed and authorized by Sunu Manuel, Company Secretary and Compliance Officer, on February 6, 2026. The company maintains its registered office at HCG Towers, Sampangi Ram Nagar, Bengaluru, and corporate office at Unity Buildings Complex, Mission Road, Bengaluru.

Network Presence

Healthcare Global Enterprises operates across multiple locations including Ahmedabad, Bengaluru, Bhavnagar, Chennai, Cuttack, Hubballi, Indore, Jaipur, Kalaburagi, Kenya, Kolkata, Mumbai, Nagpur, Nashik, Ongole, Rajkot, Ranchi, Shimoga, Vadodara, Vijayawada, and Vizag, establishing itself as a comprehensive cancer care provider.

Healthcare Global Enterprises Limited has successfully concluded its postal ballot process, with shareholders providing overwhelming approval for variations to the consultancy arrangement with Dr B.S. Ajaikumar. The company announced the results on January 22, 2026, following the completion of the e-voting process and scrutinizer's report.

Voting Results and Participation

The postal ballot, conducted exclusively through e-voting, demonstrated strong shareholder participation and support. The voting statistics reveal significant engagement across all shareholder categories:

The resolution received approval from 98.32% of the valid votes cast, with 10,15,52,724 shares voting in favor and 17,31,979 shares voting against the proposal.

E-Voting Process Details

The postal ballot process was conducted in accordance with Section 110 of the Companies Act, 2013, and related regulations. Key process parameters included:

The company sent the postal ballot notice exclusively via email to members whose email addresses were available, following MCA circulars related to COVID-19 guidelines. The voting was unblocked on January 21, 2026, at 5:00 PM for scrutiny.

Resolution Details and Approval

The ordinary resolution sought approval for variations to the consultancy arrangement with Dr B.S. Ajaikumar, in which the promoter and promoter group had declared interest. The resolution was categorized as an ordinary resolution requiring simple majority approval.

The scrutinizer's report, prepared by V. Sreedharan & Associates, confirmed the validity of the e-voting process and results. All votes cast through the electronic system were verified against the Register of Members and list of beneficiaries as of the cut-off date.

Regulatory Compliance and Documentation

The company has fulfilled all regulatory requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results have been communicated to both NSE and BSE, where the company's shares are listed under the symbols HCG and 539787 respectively.

The scrutinizer's report noted that 239 members initially participated in e-voting, with one abstention and minor adjustments resulting in 238 valid participants. Three members voted partially in favor and partially against the resolution, demonstrating the granular nature of the e-voting system.